AFFiRiS initiates preclinical development of Parkinson’s vaccine
On successful conclusion of this preclinical evaluation, initial clinical testing could start in 2010/11, the company said. The Parkinson’s vaccine specifically targets the alpha-synuclein (alpha-syn) protein, which is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.